OBJECTIVE: To determine the ability of mastic monotherapy to eradicate Helicobacter pylori infection from mice. MATERIALS AND METHODS: The susceptibility of H. pylori SS1 to mastic was assessed by broth dilution determination of the MIC and MBC. Mice were inoculated intragastrically with either a suspension of H. pylori SS1 (n = 70) or brain-heart infusion broth alone (n = 10). Mice were given antimicrobial chemotherapy 4 weeks after infection and were administered the mouse equivalent of either 2 g of mastic twice daily for 7 days or a triple therapy regimen containing the mouse equivalent of 400 mg of metronidazole, 250 mg of clarithromycin and 20 mg of omeprazole twice daily for 7 days. Mice were killed either immediately or 1 month after the completion of treatment, and their stomachs cultured for H. pylori. RESULTS: The mastic MIC and MBC of H. pylori SS1 were 7.80 and 31.25 mg/L, respectively. The triple therapy regimen eradicated infection from 19 of 20 SS1-infected mice. Mastic failed to eradicate infection from any of the 18 SS1-infected mice (P < 0.001) and there was no signifi- cant reduction in gastric bacterial load in mice treated with this regimen. CONCLUSION: Despite reported beneficial effects in ulcer patients and the good in vitro activity of mastic against H. pylori, this compound is unable to eradicate H. pylori infection from mice.
OBJECTIVE: To determine the ability of mastic monotherapy to eradicate Helicobacter pyloriinfection from mice. MATERIALS AND METHODS: The susceptibility of H. pylori SS1 to mastic was assessed by broth dilution determination of the MIC and MBC. Mice were inoculated intragastrically with either a suspension of H. pylori SS1 (n = 70) or brain-heart infusion broth alone (n = 10). Mice were given antimicrobial chemotherapy 4 weeks after infection and were administered the mouse equivalent of either 2 g of mastic twice daily for 7 days or a triple therapy regimen containing the mouse equivalent of 400 mg of metronidazole, 250 mg of clarithromycin and 20 mg of omeprazole twice daily for 7 days. Mice were killed either immediately or 1 month after the completion of treatment, and their stomachs cultured for H. pylori. RESULTS: The mastic MIC and MBC of H. pylori SS1 were 7.80 and 31.25 mg/L, respectively. The triple therapy regimen eradicated infection from 19 of 20 SS1-infectedmice. Mastic failed to eradicate infection from any of the 18 SS1-infectedmice (P < 0.001) and there was no signifi- cant reduction in gastric bacterial load in mice treated with this regimen. CONCLUSION: Despite reported beneficial effects in ulcerpatients and the good in vitro activity of mastic against H. pylori, this compound is unable to eradicate H. pyloriinfection from mice.
Authors: Andriana C Kaliora; Maria G Stathopoulou; John K Triantafillidis; George V Z Dedoussis; Nikolaos K Andrikopoulos Journal: World J Gastroenterol Date: 2007-02-07 Impact factor: 5.742